Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
BS-181 HCl (BS181; BS 181), the hydrochloride salt of BS181, is a novel, highly selective, and small molecule Cyclin-dependent kinase 7 (CDK7) inhibitor with potential antitumor activity. Through a cell-free assay, it inhibits CDK7 with an IC50 of 21 nM. It exhibits a selectivity of over 40 times for inhibiting CDK7 as opposed to CDK1, 2, 4, 5, 6, or 9.
Targets |
PPARβ/δ (IC50 = 22.9 μM)
|
---|---|
ln Vitro |
BS-181 suppresses the growth of cancer cells and induces cell cycle arrest; its IC50 values range from 11.5 to 37 μM, and its effects are seen in all tested cell lines. With an apparent IC50 of 15 μM, BS-181 inhibits RB phosphorylation at Ser795 and Ser821, which is comparable to the IC50 found for P-Ser2 inhibition. MCF-7 cells treated with BS-181 undergo apoptosis and G1 arrest[1]. The growth of normal gastric epithelial RGM-1 cell line and GC cell line is inhibited by BS-181, with inhibitory concentrations (IC50) ranging from 6.5 μM to 17 to 22 μM. In a dose-dependent manner, BS-181 dramatically reduces the ability of cells to migrate and invade[2].
|
ln Vivo |
MCF-7 tumor growth is inhibited in nude mice by BS-181 (5 mg/kg, 10 mg/kg, i.p.). Administration of 10 mg/kg BS-181 intravenously (i.v.) and intraperitoneally (i.p.) results in fast clearance[1]. Comparing the treated group to the control, BS-181 (10 mg/kg/d or 20 mg/kg/d, i.p.) significantly and dose-dependently inhibits the growth of the tumor[2].
|
Enzyme Assay |
The purified recombinant CDK7/CycH/MAT1 complex is incubated with increasing concentrations of BS-181 to measure the amount of inhibited CDK7 activity. The amount of free ATP that remains in the reaction is then measured using a luciferase assay, and the luciferase activity provides a measure of the inhibition of CDK7 activity for IC50 calculation.
|
Cell Assay |
The supplier's introduction states that the Cell Counting Kit (CCK-8 kit) is used to detect cell viability. In a nutshell, 104 BGC823 cells are seeded per well for 48 hours, either with or without BS-181. Next, each well's absorbance is measured at 450 nm (with a reference at 650 nm).
|
Animal Protocol |
The mice receive a subcutaneous injection of 5×106 BGC823 cells (0.1 mL) in their flanks. Tumor sizes are measured twice a week, and volumes are computed with the following formula: tumor size = (length ×width2)/2. Ultimately, thirty mice with tumor volumes ranging from 100 to 200 mm3 are chosen, and they are randomly assigned to three groups. BS-181 is made in the following conditions: 10% dimethyl sulfoxide/50 mM HCl/5% Tween 20/85% saline, as previously mentioned. For 14 days, mice are given BS-181 injection (ip) twice a day at the prescribed doses (10 mg/kg/d for BS-181 or 20 mg/kg/d for Roscovitine). Injectable vehicles are given to control mice. Daily measurements of the tumor volume and animal weights are made during the course of the 14-day treatment. To observe their survival, all rats are also held for an additional 30 days. In mice, BS-181 at a dose of 5 mg/kg or 10 mg/kg is administered intraperitoneally twice a day.
|
References |
|
Molecular Formula |
C22H32N6.HCL
|
|
---|---|---|
Molecular Weight |
416.99
|
|
Exact Mass |
416.2455228
|
|
CAS # |
1397219-81-6
|
|
Appearance |
solid
|
|
SMILES |
CC(C)C1=C2N=C(C=C(N2N=C1)NCC3=CC=CC=C3)NCCCCCCN.Cl
|
|
InChi Key |
NVIJWMOQODWNFN-UHFFFAOYSA-N
|
|
InChi Code |
InChI=1S/C22H32N6.ClH/c1-17(2)19-16-26-28-21(25-15-18-10-6-5-7-11-18)14-20(27-22(19)28)24-13-9-4-3-8-12-23;/h5-7,10-11,14,16-17,25H,3-4,8-9,12-13,15,23H2,1-2H3,(H,24,27);1H
|
|
Chemical Name |
5-N-(6-aminohexyl)-7-N-benzyl-3-propan-2-ylpyrazolo[1,5-a]pyrimidine-5,7-diamine;hydrochloride
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
|
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.3981 mL | 11.9907 mL | 23.9814 mL | |
5 mM | 0.4796 mL | 2.3981 mL | 4.7963 mL | |
10 mM | 0.2398 mL | 1.1991 mL | 2.3981 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.